Exogenus’ core technology makes use of Extracellular Vesicles released by Umbilical Cord Blood cells, purified by a proprietary production process, and characterized using standardized methods implemented at our company.

Rather than being seen as medical waste, umbilical cord blood (UCB) has received great interest in the past three decades for its use as a medicinal product. Since the first UCB transplant in the late 1980s‚ this cellular therapy has been used mostly for the treatment of leukemias, as well as other malignant and non-malignant disorders¹. Data from 2014 shows that over 40.000 transplants have been performed in Europe¹, a number that is estimated to continue growing as UCB banking increases. It is worth noting that cryopreservation of UCB can remain therapeutically valuable for at least 20 years, without significant changes to its hematopoietic stem cell viability or engrafting capability².

The interest around UCB lies not only on its richness in hematopoietic stem and progenitor cells³, but also on its potential usefulness for regenerative medicine and immune modulation⁴. Several clinical trials are currently investigating the use of UCB for a number of diseases, including type I diabetes, stroke and viral infections⁵.

Exogenus Therapeutics endorses the potential of UCB as a raw material for the treatment of regenerative and immunological disorders, and is actively contributing to advance the field of UCB-derived medicinal products.

References